[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsIntervention group: Patients in this group receive tocilizumab at a dose of 8 mg/kg (up to a maximum dose of 800 mg/kg) by two consecutive intravenous infusions 12 hours apart in addition to standard treatment based on national guidelines for the treatment and management of COVID-19.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PlaceboControl group: Patients in this group receive a placebo at a dose of 8 mg/kg (up to a maximum dose of 800 mg/kg) by two consecutive intravenous infusions 12 hours apart in addition to standard treatment based on national guidelines for the treatment and management of COVID-19.", "treatment_type": "TODO", "pharmacological_treatment": "Placebo"}]

[{"arm_notes": "", "treatment_id": 1299, "treatment_name": "Tocilizumab", "treatment_type": "Interleukin inhibitors", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]